SAN FRANCISCO - A new risk model for myelodysplastic syndrome provides survival projections that apply to patients at any stage of the disease, researchers at The University of Texas M. D. Anderson ...
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study A total of 1,471 MDS patients with comprehensively annotated clinical and molecular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results